NDAs

Correlations have been found between certain absorption patterns in the infrared and the concentrations of aromatic and paraffinic carbons given by the ndA/method (see article 3.1.3.). The absorptions at 1600 cm due to vibrations of valence electrons in carbon-carbon bonds in aromatic rings and at 720 cm (see the spectrum in Figure 3.8) due to paraffinic chain deformations are directly related to the aromatic and paraffinic carbon concentrations, respectively. )... 

Dmg products must meet the requirements estabUshed by the Center for Dmg Evaluation and Research at FDA. They must comply with the appropriate OTC Dmg Review Fiaal Rule pubHshed ia the Federal Register or must be the subject of an approved New Dmg AppHcation (NDA) filed with FDA. Products not meeting these requirements are considered by FDA to be New Dmgs without an NDA and subject to regulatory action. 

FDA has pubHshed two final rules for hair products as of this writing (69). Any over-the-counter (OTC) dmg product labeled or promoted for external use as a hair grower or for hair loss prevention is regarded as a new dmg and must be the subject of an approved new dmg appHcation (NDA). Products making these claims without an NDA are considered to be ia violation of the Federal Food, Dmg and Cosmetic Act and are also mislabeled. 

The conditions whereby dandmff, seborrheic dermatitis, and psoriasis dmg products are generally recognized as safe and effective and are not misbranded is available (70). Specific active iagredients that can be used as well as the statement of identity, iadications for use, and required warnings, are identified. Products that do not meet all of these requirements are considered new dmgs and must have an approved NDA for the nonmonograph conditions. 

The U.S. Eood and Dmg Administration (EDA) approved 22 new dmgs and one biotech medicine during 1994. These new dmg entities had an adjusted average review time of 19.7 months, from filing of the New Dmg AppHcation (NDA) at the EDA to time of approval. This was down from the 25.6 months for the 26 new entities approval in 1993. In the total dmg development and approval process it takes approximately 12 years for an experimental... 

In the United States, through the NDA review process, pharmaceutical companies that seek FDA approval for new dmg products are assessed user fees by FDA to gain faster approval, by virtue of the U.S. Prescription Dmg User Fee Act of 1992. These assessments are used to increase the new dmg review staff of the FDA, which has agreed to reduce the NDA review time to 12 months by 1997 (6). 

Einahy, all data, including the results of the clinical investigation, ate collected in a New Dmg Apphcation (NDA) and sent to the EDA. Once approved, the new dmg goes into production. After manufacturing begins, the new dmg products must be monitored in clinical use in the marketplace for reports of untoward reactions. This amounts to post-approval surveillance known as Phase IV. All such reports must be submitted to the EDA in a timely manner. 

New dmg apphcation (NDA) is the process through which the U.S. Food and Dmg Administration (FDA) authorizes the marketing of a new dmg. In the NDA, the data are intended to demonstrate the safety and efficacy of the dmg in its intended apphcation. After approval, the dmg becomes available to the pubhc. Subsequendy, dosage amounts and forms may be modified according to experience, new indications may be added, and contraindications may be noted. All of the changes requite regulatory approval. A dmg in human use is subject to constant surveillance. 

PEN film for audio- and videotape and various electronic appHcations and blow molded PEN containers for hot-fill appHcations are already being marketed in Japan. NDA is unlikely to ever become as inexpensive as terephthaUc acid but novel NDA-based polyesters will become available if a market need exists. One example could be the experimental polyester PBN (Celanese Corp.) this is the NDA analogue of PBT, poly(l,4-butylene naphthalene-2,6-dicarboxylate) [28779-82-0]. It has a high rate of crystallization, faster even than that of PBT, and its combination of physical properties is weU-suited for injection molding. 

Naphthalene-2,6-Dicarboxylic Acid. NDA is more compHcated to synthesize on an industrial scale. The preferred starting material is... 

Another problem arises from brominated aromatic species derived from inorganic bromides used as oxidation cocatalysts. As a result, the cmde NDA is converted to its dimethyl ester, DMNDA [840-65-3] and solvent recrystalHzed to give a high purity diester (36—38). A process for purifying NDA directly by hydrogenation (pure TA process) has also been described (39). 

Du Pont s Zenite range of LCPs have been reintroduced. These materials are also LCP polyesters based on HBA copolymers with, it is beheved, various amounts of 4,4 -biphenol, terephthaUc acid, and naphthalene-2,6-dicatboxyhc acid (NDA) as comonomers. Their compositions are thus similar to those of XYDAR with added NDA to further reduce the melting point (235,236). 

Wa.ter Qua.litySta.nda.rds, The first step in water quahty standards is stream use classification. The individual states must decide what the uses of their water will be. The four categories, as defined by the EPA, are Class A, primary water contact recreation Class B, propagation of desirable aquatic life Class C, pubHc water suppHes prior to treatment and Class D, agricultural and industrial uses. States may vary the definition of these classes to meet their own needs. The second step is to develop water-quaHty criteria. This is the specific concentration of a pollutant that is allowable for the designated use. 

In order to be approved, an NDA must include data which demonstrate that the dmg is both safe and effective. Each NDA is assigned to a division within ODER for consideration and adnunistrative control, and then assigned to the appropriate therapeutic group within the division for review. The primary team of reviewers typically consists of a physician, a pharmacologist or toxicologist, and a chemist. 

Another distinct class of dmgs are those requiring a prescription or a written order from a physician or health professional. Congress authorized PDA to determine whether a dmg should be a prescription dmg. Typically prescription dmgs are those that (/) have habit-forming characteristics (2) requke a physician s supervision, because of toxic or other harmful effects, methods of use, or coUateral measures necessary for use or (J) are limited to prescription use under an NDA. 

Cla.ss II Performance Sta.nda.rds. This category regulates devices for which General Controls are not sufficient to ensure safety and effectiveness. Class 11 controls iaclude all the controls ia Class 1. In addition, manufacturers of sutures ia Class 11 must give the EDA 90-days notice of their iatent to market the suture, by way of a 510(k) filing providing data to show that the suture is "substantially equivalent" to an already-approved device. Most sutures were reclassified iato Class 11 ia 1989. Other than USP standards, performance standards for sutures have not actually been promulgated, but the EDA has taken the stand that sufficient information exists ia the pubHshed Hterature to ensure the safety and effectiveness of sutures ia this class. 

New dmg appHcation (NDA) filing or approval. Launch date in Japan. 

MoriciZine. Moricizine, a phenothiazine derivative, was synthesized and developed in Russia, where it has been in general use since 1971. EDA approval of the new dmg application (NDA) for use in the United States was granted in 1991. It is effective against atrial and ventricular arrhythmias (1,2,21). 

In contrast to prescription dmgs, OTC dmgs and cosmetics are not subject to preclearance in the United States. However, the rules covering OTC dmgs preclude introduction of untested dmgs or new combinations. A "new chemical entity" that appears suitable for OTC dmg use requires work-up via the new dmg appHcation (NDA) process. In contrast, the use of ingredients in cosmetics is essentially unrestricted and may include less well known substances. 

The first of the Wong/Sandler mixing rules relates the difference in mixture quantities b a.nda/RT to the corresponding differences (identified by subscripts) for the pure species ... 

Drug Animal tests, Phase Phase II Phase III NDA Ongoing... 

New drug application (NDA), 165 New 1UPAC naming system, 177 New molecular entity (NME), number of, 164... 

F3. Firstenberg, H., Goldmann, K., Lo Bianco, L., Preiser, S., and Rabinowitz, G., Compilation of experimental forced convection quality burnout data with calculated Reynolds numbers, NDA-2131-16 (1960). 

A New Drug Application (NDA) is submitted after tiie investigation of the drug in Phases I, II, and III is... 

---